The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes.
5-azacytidine
dose reduction
myelodysplastic syndrome
prognosis
treatment delay
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
06
06
2020
accepted:
30
07
2020
pubmed:
31
8
2020
medline:
3
8
2021
entrez:
31
8
2020
Statut:
ppublish
Résumé
The regimen of 5-azacytidine for patients with myelodysplastic syndrome (MDS) has remained unchanged since its first approval. Although several modifications have since been made and delays and dose reductions are common especially during the first treatment cycles, there are minimal data on the prognostic effect of these modifications. In this study, based on data from 897 patients with MDS treated with 5-azacytidine recorded in a national registry, the effect of treatment delays and dose reductions on response, transformation to acute myeloid leukaemia, and survival (after 5-azacytidine initiation, OS
Substances chimiques
Azacitidine
M801H13NRU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
978-987Subventions
Organisme : Genesis Pharma
ID : GE00036/2018
Informations de copyright
© 2020 British Society for Haematology and John Wiley & Sons Ltd.
Références
Medicines.org.uk. Vidaza 25 Mg/Ml Powder For Suspension For Injection - Summary Of Product Characteristics (Smpc) - (Emc). 2020. Available at https://www.medicines.org.uk/emc/product/6468/smpc [Accessed 2 May 2020].
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional careregimens in the treatment of higher-risk myelodysplasticsyndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223-32.
Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of Azacitidine in patients with the Myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429-40.
Ams M, Florek M. Small molecules in oncology. 2. New York: Springer Heidelberg; 2014. 5-Azacytidine; pp. 299-324.
Morita Y, Maeda Y, Yamaguchi T, Urase F, Kawata S, Hanamoto H, et al. Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): a prospective single-arm phase 2 trial. Cancer Sci. 2018;109(10):3209-15.
Laribi K, Bolle D, Alani M, Ghnaya H, Besançon A, Farhi J, et al. Impact of the relative dose intensity on survival of patients with high-risk myelodysplastic syndromes treated with Azacitidine. Cancer Med. 2019;8(5):2188-95.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405.
Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood;89(6):2079-88. Erratum in Blood 1998;91:1100.
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.
International Standing Committee on Human Cytogenetic Nomenclature; Shaffer LG, Tommerup N. ISCN 2005: an international system for human cytogenetic nomenclature (2005): recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Basel; Farmington, CT: Karger; 2005. 130 pp.
Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419-25.
Lorenzana N, Avila LF, Alonso S, Colado E, Bernal T. The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment. Ann Hematol. 2017;96(11):1833-40.
Caira M, Latagliata R, Girmenia C. The risk of infections in patients with myelodysplastic syndromes in 2016. Expert Rev Hematol. 2016;9(6):607-14.
Silverman LR, Holland JF, Weinberg RS, Alter BP, Davis RB, Ellison RR, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993;7(Suppl 1):21-9.
Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24(24):3895-903.
Santini V, Ossenkoppele GJ. Hypomethylating agents in the treatment of acute myeloid leukemia: a guide to optimal use. Crit Rev Oncol Hematol. 2019;140:1-7.